



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 March 2012
EMA/198067/2012
Press Office

Medicines granted a Community marketing authorisation under the centralised procedure

From 01 February 2012 to 29 February 2012

Invented name	Colobreathe
INN	colistimethate sodium
Marketing Authorisation Holder	Forest Laboratories UK Ltd
Proposed ATC code	Not yet assigned
Indication	Management of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis (CF) aged 6 years and older
CHMP opinion date	22/09/2011
Marketing authorisation date	17/02/2012

Invented name	Vepacel
INN	Prepandemic influenza vaccine (A/H5N1) (whole virion, Vero cell derived, inactivated)
Marketing Authorisation Holder	Baxter Innovations GmbH
Proposed ATC code	J07BB01
Indication	Active immunisation against H5N1 subtype of influenza A virus.
CHMP opinion date	15/12/2011
Marketing authorisation date	17/02/2012

